P2-068: CD63 as a biomarker for predicting the clinical outcomes in non-small cell lung cancers

Abstract

Background: The prognosis of lung cancer is still poor, since there are few early detection tools available yet. So, it is important to identify more efficient and clinically applicable biomarkers associated with the prognosis in as earlier stages as possible. Method: In this study, we firstly observed the expression profile of CD63 in 33 cases of non-small cell lung cancers (NSCLC) using realtime quantitative RT-PCR. To explore the potential of this molecule as a prognostic biomarker for lung cancer subtypes, we constructed tissue microarrays with 90 NSCLCs. Then immunohistochemistry analysis